Abstract
The expression levels of miR-365 vary in different malignancies. Herein, we found that miR-365 was overexpressed in both cells and clinical specimens of cutaneous squamous cell carcinoma (SCC). We demonstrated that the HaCaT(pre-miR-365-2) cell line, which overexpressed miR-365, could induce subcutaneous tumors in vivo. Antagomir-365, an anti-miR-365 oligonucleotide, inhibited cutaneous tumor formation in vivo, along with G1 phase arrest and apoptosis of cancer cells. These findings suggest that miR-365 may act as an onco-miR in cutaneous SCC both in vitro and in vivo. The present study provides valuable insight into the role of miR-365 in cutaneous SCC formation, which can help develop new drug and miR-365 target-based therapies for cutaneous SCC.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Apoptosis
-
Carcinoma, Squamous Cell / genetics*
-
Carcinoma, Squamous Cell / pathology
-
Carcinoma, Squamous Cell / therapy
-
Cell Line, Tumor
-
Female
-
G1 Phase Cell Cycle Checkpoints
-
Gene Expression Regulation, Neoplastic*
-
Humans
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Mice, Nude
-
MicroRNAs / genetics
-
MicroRNAs / metabolism*
-
Middle Aged
-
Neoplasm Staging
-
Neoplasm Transplantation / pathology
-
Oligoribonucleotides, Antisense / administration & dosage
-
RNA, Neoplasm / genetics
-
RNA, Neoplasm / metabolism*
-
Skin Neoplasms / genetics*
-
Skin Neoplasms / pathology
Substances
-
Antineoplastic Agents
-
MIRN365 microRNA, human
-
MicroRNAs
-
Oligoribonucleotides, Antisense
-
RNA, Neoplasm